AbbVie Inc. (4AB)
FSX
Closed
Oct 7, 2026
Day's Range
236.3052 wk Range
167.55Overview - 4AB - AbbVie Inc.
Key Statistics
Valuation
Enterprise Value
429.50B
P/E (Trailing)
‪79.43‬
P/E (Forward)
‪17.22‬
PEG Ratio
‪0.27‬
Price / Sales (TTM)
‪6.60‬
Price / Book
‪-73.46‬
EV / EBITDA
‪15.72‬
Profitability
Gross Margin
‪74.74%‬
Profit Margin
‪9.80%‬
Operating Margin
‪40.03%‬
Return on Assets
‪10.51%‬
Return on Equity
‪-129.67%‬
Ownership
Shares Outstanding
1.76B
Float
1.76B
Held by Insiders
‪0.11%‬
Held by Institutions
‪77.33%‬
Price stats
Beta
‪0.22‬
50-Day Avg
‪223.70‬
200-Day Avg
‪199.74‬
Dividends
Payout Ratio
‪190.39%‬
Frequency
Quarterly
Market Cap - 4AB - AbbVie Inc.
Peers - 4AB - AbbVie Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on FSX.
- 4ABFSXAbbVie Inc.432.59BMarket Cap+18.10%52-week change79.44P/E (Trailing)‪9.80%‬Profit Margin
- LLYFSXEli Lilly and Company910.25BMarket Cap+29.50%52-week change38.89P/E (Trailing)‪33.52%‬Profit Margin
- LLY0FSXEli Lilly CDR836.52BMarket Cap+33.20%52-week change36.06P/E (Trailing)‪33.52%‬Profit Margin
- JNJFSXJohnson & Johnson574.39BMarket Cap+35.37%52-week change31.44P/E (Trailing)‪21.48%‬Profit Margin
- JNJ0FSXJohnson & Johnson CDR525.52BMarket Cap+34.43%52-week change28.65P/E (Trailing)‪21.48%‬Profit Margin
- 4AB0FSXAbbVie Inc. CDR360.66BMarket Cap+15.74%52-week change65.45P/E (Trailing)‪9.80%‬Profit Margin
- 6MKFSXMerck & Co., Inc.320.43BMarket Cap+48.57%52-week change118.07P/E (Trailing)‪4.76%‬Profit Margin
Profile Summary - 4AB - AbbVie Inc.
About
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
